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Abstract The Pro47Ser variant of p53 (S47) exists in African-descent populations and is
associated with increased cancer risk in humans and mice. Due to impaired repression of the
cystine importer Slc7a11, S47 cells show increased glutathione (GSH) accumulation compared to
cells with wild -type p53. We show that mice containing the S47 variant display increased mTOR
activity and oxidative metabolism, as well as larger size, improved metabolic efficiency, and signs
of superior fitness. Mechanistically, we show that mTOR and its positive regulator Rheb display
increased association in S47 cells; this is due to an altered redox state of GAPDH in S47 cells that
inhibits its ability to bind and sequester Rheb. Compounds that decrease glutathione normalize
GAPDH-Rheb complexes and mTOR activity in S47 cells. This study reveals a novel layer of
regulation of mTOR by p53, and raises the possibility that this variant may have been selected for
in early Africa.
Introduction
The p53 tumor suppressor protein serves as a master regulator of the cellular response to intrinsic
and extrinsic stress. Mutations in the TP53 gene occur in more than 50% of human cancers, and this
gene is well known as the most frequently mutated gene in cancer (Hollstein et al., 1991). p53
works to suppress uncontrolled cellular growth and proliferation through various pathways including
apoptosis, senescence, cell cycle arrest, and ferroptosis (Stockwell et al., 2017; Vousden and
Prives, 2009). More recently, a role for p53 in the control of metabolism has emerged. The meta-
bolic functions of p53 include the regulation of mitochondrial function, autophagy, cellular redox
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state, and the control of lipid and carbohydrate metabolism; for review see Berkers et al., 2013;
Gnanapradeepan et al., 2018.
As an integral part of its control of metabolism, p53 negatively regulates the activity of mTOR
(mammalian target of rapamycin), which is a master regulator of metabolism in the cell. mTOR is a
serine-threonine protein kinase that is stimulated by mitogenic signals, and phosphorylates down-
stream targets that in turn regulate protein synthesis and cell growth (Ben-Sahra and Manning,
2017). mTOR exists in two distinct signaling complexes: mTORC1 is primarily responsible for cell
growth and protein synthesis, while mTORC2 plays roles in growth factor signaling, cytoskeletal con-
trol, and cell spreading (Liu and Sabatini, 2020). Not surprisingly, mTOR activity is frequently upre-
gulated in a diverse range of cancers. p53 negatively regulates the mTOR pathway in part through
transactivation of the target genes PTEN, TSC2, PRKAB1 and SESN1/SESN2 (Budanov and Karin,
2008; Feng et al., 2005). The regulation of mTOR by p53 is believed to couple the control of
genome integrity with the decision to proliferate (Hasty et al., 2013).
TP53 harbors several functionally impactful genetic variants or single-nucleotide polymorphisms
(SNPs) (Basu et al., 2018; Jennis et al., 2016; Kung et al., 2016). A naturally occurring SNP in TP53
exists at codon 47, encoding serine instead of a proline (Pro47Ser, rs1800371, G/A). This variant
exists predominantly in African-descent populations, and occurs in roughly 1% of African Americans
and 6% of Africans from sub-Saharan Africa (Murphy et al., 2017). The S47 variant is associated
with increased risk for pre-menopausal breast cancer in African American women (Murphy et al.,
2017). In a mouse model, the S47 mouse develops markedly increased incidence of spontaneous
cancer, particularly hepatocellular carcinoma (Jennis et al., 2016). This variant is likewise defective in
the regulation of the small subset of p53 target genes that play roles in ferroptosis sensitivity, includ-
ing the cystine importer SLC7A11. As a result, increased levels of cysteine and glutathione (GSH)
accumulate in cells from S47 humans and mice (Jennis et al., 2016; Leu et al., 2019). More recently,
we showed that the ferroptotic defect in S47 mice leads to iron accumulation in their livers, spleens,
and macrophages. We also showed that the S47 variant is positively associated with markers of iron
overload in African Americans (Singh et al., 2020).
An emerging paradigm in the cancer literature is that tumor-predisposing genetic variants may
paradoxically provide selection benefit to individuals, thus potentially explaining the frequency of
these damaging alleles in the population. As an example, women carrying tumor-predisposing muta-
tions in the BRCA1 gene tend to be physically larger and show increased fertility (Smith et al.,
2012). Here-in we show that mice carrying a knock-in S47 allele in a pure C57Bl/6 background show
increased size, lean content (muscle), and metabolic efficiency, relative to littermate mice with WT
p53. We report that mouse and human S47 cells show a significant increase in mTOR activity, due in
part to increased mTOR-Rheb binding in S47 cells. We propose that these attributes may have led
to a positive selection for this variant in sub-Saharan Africa. Our studies shed further light on the
intricate regulation that exists between p53, mTOR activity, and metabolic output, in this case medi-
ated by GSH and the control of cellular redox state.
Results
Higher basal mTOR activity in cells containing the S47 variant
We previously showed that human lymphoblastoid cells (LCLs) that are homozygous for the S47 vari-
ant of p53 are impaired for the transcriptional regulation of less than a dozen p53 target genes,
compared to cells from individuals from the same family containing WT p53 (Jennis et al., 2016).
We noted that several of these genes encode proteins that play roles in the negative regulation of
mTOR (Budanov and Karin, 2008; Feng et al., 2007). We confirmed via qRT-PCR that S47 LCLs
show modestly decreased expression of the p53 target genes SESN1 and PTEN, and decreased
transactivation of PRKAB1, relative to WT LCLs following cisplatin treatment (Figure 1—figure sup-
plement 1A and B). These findings prompted us to assess basal mTOR activity in WT and S47 LCLs,
and in MEFs from WT and S47 mice. To corroborate our findings, we also analyzed tissues from
humanized p53 knock-in (Hupki) mice carrying WT and S47 alleles on a pure C57Bl/6 background,
which we previously generated and characterized (Jennis et al., 2016). Western blot analysis of WT
and S47 LCLs, along with multiple clones of WT and S47 MEFs, revealed increased p-S6K1 (Thr389)
in S47 cells (Figure 1A). Following normalization to total S6K1, this increase ranged between two-
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Figure 1. Increased markers of mTOR activity in S47 cells and tissues. (A) Western blot analyses reveal higher phospho-S6K1 expression in S47 LCLs
and S47 MEFs; the latter were obtained from two separate embryos per genotype. (B) Densitometry quantification of phospho-S6K1 protein expression
in WT and S47 MEFs from four independent experiments; all values normalized to total S6K1. Error bars represent standard error, (*) p value < 0.05. (C)
Whole cell lysates were extracted from three WT and three S47 mouse lungs and analyzed by western blot for the proteins indicated. Pairs 1 and 3 are
lungs isolated from male mice, pair 2 is lungs isolated from female mice. Densitometry quantification of phospho-S6K1 and phospho-mTOR was
performed and normalized to total S6K1 and total mTOR protein expression, respectively. (D) Whole cell lysates were extracted from WT and S47
mouse skeletal muscle and analyzed as described above. Densitometry quantification of phospho-S6, phospho-S6K1, phospho-mTOR was performed
and normalized to total S6, total S6K1 and total mTOR protein expression, respectively. (E) Immunohistochemical analysis of hematoxylin and eosin (H
and E), phospho-mTOR and phospho-S6K1 in WT and S47 mouse lung and skeletal tissue. Data are representative of n = 4 mice per genotype. Scale
Figure 1 continued on next page
Gnanapradeepan et al. eLife 2020;9:e55994. DOI: https://doi.org/10.7554/eLife.55994 3 of 25
Research article Cancer Biology
and threefold (Figure 1B). We next compared mTOR activity in age- and sex-matched pairs of lung
and muscle tissue from WT and S47 mice; we did this because mTOR activity is influenced by age
and gender, and there is increased mTOR activity in female and older mice (Baar et al., 2016). We
found increased levels of p-S6K1 (T389) and p-mTOR (Ser2448) in S47 lung and skeletal muscle, rela-
tive to WT tissues (Figure 1C and D). Immunohistochemical analysis of tissues from multiple age-
and sex-matched WT and S47 mice confirmed these findings (Figure 1E). Interestingly, increased
mTOR activity was not seen in all tissues of the S47 mouse (Figure 1—figure supplement 1C), and
lung and skeletal muscle were the most consistently different between WT and S47. We also did not
detect significant differences in p-AKT (Ser473) in WT and S47 lung tissue, suggesting that mTORC1
and not mTORC2 is likely responsible for the observed differences in mTOR activity (Figure 1—fig-
ure supplement 1D).
We next sought to test the kinetics of mTOR activation in WT and S47 cells by subjecting early
passage WT and S47 MEFs to nutrient deprivation, followed by monitoring of mTOR activation
markers after nutrient restoration using antisera to p-S6K1 and p-mTOR. Glucose deprivation experi-
ments revealed consistent albeit modest increases in p-S6K1 following glucose refeed in S47 MEFs,
compared to WT (Figure 1F). Serum deprivation experiments revealed more pronounced results.
For serum deprivation, we subjected three independent cultures each of WT and S47 MEFs to 0.1%
serum for 16 hr, followed by 10% serum, after which total and phospho -S6K1 and -mTOR were
monitored in a time course. S47 cells consistently showed increased induction of markers of mTOR
activation after serum re-feed compared to WT cells (Figure 1G). We next performed amino acid
deprivation experiments; these likewise showed increased response in S47 cells (Figure 1—figure
supplement 1E). Combined densitometry results from all forms of nutrient deprivation revealed an
approximately two- to threefold increase in p-S6K1 in S47 cells following nutrient restoration at 30
or 60 min (Figure 1—figure supplement 1F).
Given that mTOR plays a role in autophagy inhibition (Jung et al., 2010; White et al., 2011), we
wondered whether basal autophagy or autophagic flux might be decreased in S47 cells. We were
unable to see any differences in the steady state levels of LC3B or the autophagy adaptor protein
p62SQSTM1 in WT and S47 MEFs or tissues, either at steady state (Figure 1—figure supplement 1G)
or following HBSS treatment to induce autophagy (Figure 1—figure supplement 1H). Likewise, we
failed to see differences in autophagic flux (conversion of LC3-I to LC3-II when the lysosome is inhib-
ited (Figure 1—figure supplement 1I) between WT and S47 cells, or in cell viability after HBSS
treatment (Figure 1—figure supplement 1J). Therefore, while markers of mTOR activity are clearly
increased in S47 cells and tissues, this does not appear to be accompanied by alterations of basal or
induced autophagy.
Enhanced mitochondrial function and glycolysis in S47 cells
To determine the functional consequences of the increased markers of mTOR activity in S47 cells,
we used a Seahorse BioAnalyzer to assess the oxygen consumption rate (OCR), as well as basal and
compensatory glycolytic rate in WT and S47 MEFs and LCLs. Seahorse analyses revealed that S47
LCLs show increased OCR under stressed conditions compared to WT (Figure 2A). These analyses
also revealed that human S47 LCLs and mouse S47 MEFs show increased basal and compensatory
glycolysis, compared to WT cells (Figure 2B and C). We next assessed glucose and glutamine con-
sumption using a Yellow Springs Instrument (YSI) Analyzer. These analyses revealed that S47 LCLs
and MEFs show significantly increased consumption of glucose and glutamine, along with increased
production of lactate and glutamate, compared to WT cells (Figure 2D and E); again, multiple inde-
pendent MEF lines were analyzed. Interestingly, LCLs from individuals heterozygous for the S47
Figure 1 continued
bar represents 100 mm. (F) WT and S47 MEFs were grown in glucose-free media for 16 hr, then in media containing 4.5 g/L glucose. Samples were
collected at indicated time points and analyzed by western blot for p-S6K1, total S6K1, and GAPDH. (G) WT and S47 MEFs were cultured in media
containing 0.1% FBS for 16 hr, followed by media containing 10% serum and samples were collected at indicated time points. Cell lysates were
extracted from samples and subjected to western blot analysis for the proteins indicated.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Altered metabolic markers in S47 cells and tissues.
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Figure 2. Increased metabolism in S47 cells compared to WT cells. (A) Oxygen consumption rates (OCR) in WT
and S47 LCLs were assessed using the Seahorse XF Mito Stress Test. OCR was measured first in basal conditions,
and following injection of oligomycin, FCCP and rotenone/antimycin. The bar graph depicts maximal OCR after
FCCP injection at ~40 min timepoint; data are representative of three independent experiments performed with at
least six technical replicates, presented as mean ± SD. (B–C) Basal and compensatory glycolysis in WT and S47
LCLs (B) and MEFs (C) were assessed using the Seahorse Glycolytic Rate Assay. Basal glycolysis is first measured,
followed by treatment of cells with rotenone/antimycin and 2-deoxy-D-glucose (2-DG). The bar graph depicts
basal glycolysis at ~1 min timepoint and compensatory glycolysis after antimycin/rotenone injection at ~22 min
timepoint; data are representative of three independent experiments performed with at least 10 technical
replicates. Bar graphs are presented as mean ± SD. (D–E) Consumption of glucose and glutamine from media and
production of lactate and glutamate were analyzed from homozygous WT, heterozygous WT/S47 and
Figure 2 continued on next page
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variant (S47/WT), and MEFs from S47/WT mice, showed values typically intermediate between
homozygous WT and S47 cells (Figure 2D and E). We next performed metabolic flux analyses in WT
and S47 cells using 13C-labeled glucose. Analysis of 13C6-glucose tracing in WT and S47 MEFs pro-
vided evidence for a higher contribution of glucose carbon into the TCA cycle in S47 cells compared
to WT cells, as evidenced by increased labeling of citrate, malate, aspartate, and glutamate in S47
MEFs (Figure 2—figure supplement 1A–D). We reasoned that one possibility for the increased
metabolism in S47 cells might be due to increased mitochondrial content, which is regulated by
mTOR (Morita et al., 2013). However, MitoTracker analyses and western blotting for mitochondrial
proteins revealed no obvious increase in mitochondrial content in S47 cells (Figure 2—figure sup-
plement 1E and F). We find no evidence that S47 LCLs and MEFs proliferate more quickly than WT
cells (Jennis et al., 2016); this raises the possibility that this increased nutrient consumption may be
used for biomass instead of proliferation.
Because mTOR is known to regulate mitochondrial function (Morita et al., 2013; Schieke et al.,
2006; Ye et al., 2012), we next assessed the impact of mTOR inhibitors on mitochondrial function in
WT and S47 cells. Seahorse analysis of WT and S47 LCLs revealed that S47 cells are less susceptible
to inhibition of oxygen consumption rate and maximal respiration by the mTOR inhibitors rapamycin
(Figure 3A and B) and Torin1 (Figure 3C and D). This finding was not due to altered efficacy of
each inhibitor, as evidenced by similar decreases in p-mTOR and p-S6 in WT and S47 cells following
treatment with rapamycin (Figure 3—figure supplement 1A) and Torin1 (Figure 3E), and by the
finding that very high concentrations of Torin1 were able to inhibit oxygen consumption equally well
in both WT and S47 cells (Figure 3—figure supplement 1B). These data support the possibility of
an S47 dependent, but mTOR-independent, effect on OCR as well.
Increased mTOR activity in S47 is due to increased mTOR-Rheb
interaction
We next sought to identify the mechanism underlying increased mTOR activity in S47 cells. Unfortu-
nately, although we identified decreased mRNA levels of some mTOR regulators in S47 cells, we
found no evidence for significant differences at the protein level of any p53-regulated mTOR regula-
tors in steady state MEFs (Figure 4—figure supplement 1A) or following treatment with Nutlin to
induce p53 (Figure 4—figure supplement 1B). Therefore, we turned to a key regulator of mTOR
activity, the small GTPase Rheb, which binds and activates mTOR (Long et al., 2005). We monitored
the mTOR-Rheb association in WT and S47 MEFs using the technique of proximity ligation assay
(PLA), which quantitatively detects protein-protein interactions. PLA experiments revealed that there
were consistently increased mTOR-Rheb complexes in S47 cells, compared to WT; this was true in
multiple replicates, in multiple MEF clones, and using single antibody controls that showed no signal
(Figure 4A). Quantification of multiple experiments revealed an approximately two-fold increase in
mTOR-Rheb complexes in S47 cells compared to WT (Figure 4B), which is consistent with all of our
analyses of mTOR activity.
One regulator of the mTOR-Rheb interaction is the cytosolic enzyme GAPDH. This enzyme binds
to Rheb and sequesters it from mTOR in cultured cells, in a manner that is regulated by glucose lev-
els (Lee et al., 2009). First, we confirmed that the interaction between Rheb and GAPDH is detect-
able in the skeletal muscle of mice using IP-western, and moreover that this interaction is regulated
by glucose (Figure 4—figure supplement 1C). Next, we performed immunoprecipitation (IP)-west-
ern of Rheb in skeletal muscle extracts from WT and S47 mice; we found that there was increased
mTOR, and significantly decreased GAPDH, in Rheb IPs from S47 skeletal muscle compared to WT
(Figure 4C). The combined data from three independent IPs of Rheb in WT and S47 skeletal muscle
Figure 2 continued
homozygous S47 human LCLs (D) and primary MEFs (E) using a YSI-7100 Bioanalyzer. Means and SEM are shown
(n = 5).
The online version of this article includes the following source data and figure supplement(s) for figure 2:
Figure supplement 1. Increased metabolism in S47 MEFs but no differences in mitochondrial content in WT and
S47 cells.
Figure supplement 1—source data 1. Metabolomics source data.
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revealed an approximately twofold decrease in the amount of GAPDH co-precipitating with Rheb in
S47 skeletal muscle compared to WT (p<0.05, Figure 4D). In contrast, there were no differences in
the levels of mTOR, Rheb and GAPDH in these extracts (Figure 4C – WCL, Figure 4—figure supple-
ment 1D). Consistent with our IP-western findings, PLA analyses corroborated that the GAPDH-
Rheb association is markedly decreased in S47 MEFs relative to WT MEFs (Figure 4A). Confocal
microscopy analyses revealed no significant differences in the cellular localization of Rheb at the
Figure 3. S47 mitochondria show decreased sensitivity to mTOR inhibition. (A) Oxygen consumption rate (OCR) as measured by the Seahorse XF Mito
Stress Test in WT and S47 LCLs treated with 200 nM of rapamycin for 24 hr. (B) Bar graph depicts maximal OCR after FCCP injection at ~40 min
timepoint; fold changes between rapamycin treated and untreated samples are shown. Data are representative of two independent experiments
performed with at least 10 technical replicates. (C) OCR as measured by the Seahorse XF Mito Stress Test in WT and S47 LCLs treated with 100 nM of
Torin1 for 24 hr. (D) Bar graph depicts maximal OCR after FCCP injection at ~40 min timepoint; fold changes between Torin1 treated and untreated
samples are shown. Data are representative of two independent experiments performed with at least eight technical replicates. (E) WT and S47 LCLs
were treated with 100 nM of Torin1, harvested at indicated time points after treatment and analyzed for the shown mTOR markers via western blot.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Attenuated response to mTOR inhibition in S47 cells.
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Figure 4. Increased mTOR-Rheb binding in S47 cells is due to decreased GAPDH-Rheb binding. (A–B) An in situ proximity ligation assay (PLA) was
performed in WT and S47 MEFs. Each red dot represents an interaction between mTOR-Rheb or GAPDH-Rheb as indicated; scale bar represents 50
mm. The samples were counterstained with DAPI to detect nuclei. Cells stained in the absence of one primary antibody were used as a negative control.
(B) Quantification of the mTOR-Rheb interactions, measured as the average number of PLA signals per nuclei. Data were quantified by counting the
number of cells in five random fields per experimental condition. (***) p-value<0.001, Student’s t-test. (C) Lysates extracted from WT and S47 skeletal
tissue were immunoprecipitated with anti-Rheb. The amount of co-precipitating mTOR and GAPDH, as well as immunoprecipitated Rheb, were
assessed by western blot. Whole cell lysate (WCL) is shown on the right. (D) Quantification of the amount of GAPDH bound to Rheb, divided by total
Rheb pulled down, in WT and S47 skeletal tissue, n = 3 independent experiments, (*) p-value<0.05.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. No differences in the level of mTOR regulators in WT and S47 cells.
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lysosome, as assessed by LAMP1 localization, nor were there any differences in TSC2 localization at
the lysosome in WT and S47 MEFs (Figure 4—figure supplement 1E). The combined data support
the premise that the increased mTOR activity in S47 cells may be due to increased Rheb-mTOR asso-
ciation, caused by a decreased association of Rheb with GAPDH. We sought to test this hypothesis,
and identify the underlying mechanism.
GAPDH is a multi-functional enzyme that is known to be sensitive to redox status (Brandes et al.,
2009; Chernorizov et al., 2010). We hypothesized that the increased glutathione (GSH) levels in
S47 cells (Leu et al., 2019) might alter the redox state of GAPDH and impact its ability to bind to
Rheb. We first verified that lung tissue and skeletal muscle from S47 mice possess increased GSH
compared to WT tissues, as assessed by an increased ratio of reduced versus oxidized glutathione
(GSH:GSSG) (Figure 5A). We then validated that the GSH alkylating agent diethylmaleate (DEM)
could successfully decrease the level of GSH, and the GSH/GSSG ratio, in these cells (Figure 5A);
these findings are consistent with previously published findings by our group (Leu et al., 2019).
Notably, DEM treatment of immortalized S47 MEFs (iMEFs) caused a dramatic decrease in markers
of mTOR activity (p-mTOR and p-S6K1), showing that modulation of GSH, even for as little as five
hours, can impact mTOR activity (Figure 5B). Moreover, we found that the impact of DEM on mTOR
activity was enhanced by the addition of glutamate, which decreases cystine import through system
Xc(-), leading to decreased level of GSH (Figure 5B).
We next sought to test the hypothesis that the redox state of GAPDH was altered in WT and S47
cells. Toward this end, we employed cross-linking experiments using the cysteinyl cross-linking agent
bismaleimidohexane (BMH), which cross-links cysteine residues within 13 Å by covalently conjugating
free (reduced) sulfhydryl groups (Green et al., 2001). We treated freshly isolated lung and skeletal
muscle lysates from WT and S47 mice, and from immortalized WT and S47 MEFs (iMEFs), with BMH.
Cysteinyl-crosslinked proteins were resolved on SDS-PAGE gels and compared to untreated
extracts. Notably, we found consistent differences in GAPDH cross-linking patterns in S47 samples
compared to WT, as evidenced by altered mobility of GAPDH on SDS-PAGE of BMH-treated sam-
ples (Figure 5C). Moreover, the altered mobility of GAPDH in S47 cells could be reversed following
glutathione depletion by DEM treatment (Figure 5C) or by the compound BSO (buthionine sulfoxi-
mine; Figure 5—figure supplement 1A) which inhibits GSH biosynthesis. Treatment with the com-
pound erastin, which inhibits the system Xc(-) cystine transporter and decreases GSH, also led to
altered mobility of GAPDH in S47 and WT cells (Figure 5—figure supplement 1B). We next tested
the impact of modulating GSH on the interaction between Rheb and GAPDH in WT and S47 cells
using both IP-western and PLA. By IP-western we found that supplementation of culture media with
exogenous GSH decreased the Rheb-GAPDH interaction in WT cells; conversely, depleting free GSH
using either BSO or DEM increased the Rheb-GAPDH interaction in S47 cells (Figure 5D). These
findings were corroborated using PLA, which revealed that depleting GSH using either DEM or BSO
completely restores GAPDH-Rheb complex formation and mTOR-Rheb complex formation in S47
cells, to levels equivalent to WT cells (Figure 5E and F; Figure 5—figure supplement 1C). The com-
bined data support the conclusion that the increased GSH pool in S47 cells affects the status of reac-
tive cysteines in GAPDH, and the ability of this protein to bind and sequester Rheb, thereby leading
to increased Rheb-mTOR interaction and increased mTOR activity in S47 cells.
Enhanced metabolic efficiency of S47 mice
mTOR is known to regulate body mass and muscle regeneration (Laplante and Sabatini, 2012;
Yoon, 2017). We therefore next assessed body weight and fat/lean content in age-matched male
mice of WT and S47 genotypes. We also tracked body weight with age of multiple male and female
sibling littermate mice of WT/WT, WT/S47, and S47/S47 genotypes in our colony. S47 mice showed
significantly increased weight with time, compared to WT/WT and WT/S47 sibling littermates (Fig-
ure 6—figure supplement 1A). Body composition analysis using nuclear magnetic resonance
revealed that S47 mice had significantly increased fat and lean content, compared to WT mice
(Figure 6A; Figure 6—figure supplement 1B). We next analyzed the metabolic activities of WT and
S47 mice using a comprehensive lab animal monitoring system (CLAMS) over the course of 48 hr. In
this analysis, S47 mice showed comparable locomotor activity to WT mice but reduced food intake,
oxygen consumption, and heat production (Figure 6B). These CLAMS data suggested that S47 mice
might possess enhanced metabolic efficiency compared to WT mice, and prompted us to assess the
response of WT and S47 mice to exercise challenge.
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Figure 5. Increased glutathione drives decreased GAPDH-Rheb binding in S47 cells. (A) WT and S47 lung (left) and skeletal muscle (center) were
assessed for GSH/GSSG ratio (mean ± SD, n = 3). WT and S47 immortalized MEFs (iMEFs), either untreated or treated with 50 mM DEM for 5 hr, were
analyzed for GSH/GSSG ratio (mean ± SD, n = 4). (B) WT and S47 iMEFs were untreated or treated with 50 mM of DEM or 50 mM of DEM + 0.5 mM
glutamate for 5 hr and protein lysates were analyzed by western blot for indicated mTOR markers. (C) Whole cell lysates were extracted from WT and
S47 mouse lung (left) and skeletal (center) tissue. Proteins were cross-linked with BMH, resolved by SDS/PAGE, and detected by western blotting with a
GAPDH specific antibody (Top). Untreated protein lysates were analyzed by western blot analysis for total GAPDH (Bottom). WT and S47 iMEFs were
treated with 50 mM of DEM for 5 hr and protein lysates were analyzed as described (right). (D) WT cells were treated with PBS or 3 mM GSH for 24 hr.
S47 cells were treated with PBS for 24 hr, PBS for 5 hr, 100 mM BSO for 24 hr, or 50 mM DEM for 5 hr. IP of the lysates with anti-Rheb followed by
western analysis for associated GAPDH and Rheb (top panel). The same lysates were analyzed by western blotting for GAPDH and Rheb (bottom
Figure 5 continued on next page
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We subjected WT and S47 mice to treadmill exercise with increasing intensity over time. For this
analysis, we studied eight age-matched male mice of each genotype during a 50 min forced exercise
at increasing speed and slope. During this time course, oxygen consumption and serum metabolites
were quantified. Consistent with our CLAMs experiment, S47 mice started with lower basal VO2 and
exhibited generally lower VO2 for the work being performed; however, as they approached the final,
most strenuous point of the exercise, the VO2 values in WT and S47 converged, so the VO2 range
for S47 mice was significantly greater than WT mice (Figure 6C–E). Analysis of serum metabolites
and proteins before and after exercise revealed decreased lactate dehydrogenase (LDH) levels in
the sera of S47 mice, which is indicative of decreased muscle damage in S47 mice compared to WT
(Figure 6F). Additionally, we found that Ki-67 staining in S47 skeletal muscle was consistently
increased relative to WT muscle, suggesting an enhanced ability for S47 muscle to recover (Fig-
ure 6—figure supplement 1C). In these tissues, we found no differences in p53 level or markers of
mitochondrial content (Figure 6—figure supplement 1D and E), nor were there other differences in
other serum metabolites between WT and S47 mice (Figure 6—figure supplement 1F). These exer-
cise data, like the CLAMS data, point to increased metabolic efficiency in S47 mice relative to WT
mice. To address this further, we analyzed a small cohort of WT and S47 mice on a continuous stren-
uous treadmill run. Although the numbers are small, we found that three out of four WT mice failed
to complete a 60 min strenuous run, while three out of four S47 successfully completed this run (Fig-
ure 6—figure supplement 1G).
Discussion
In this study, we report that cells and mice with the S47 variant of p53 have increased mTOR activity
and evidence for increased metabolic efficiency. The animals also display increased mass and signs
of superior fitness. Our data support the premise that the enhanced mTOR activity is due, at least in
part, to the higher levels of GSH in S47 cells and tissues. The increased GSH results in impaired abil-
ity of the redox sensitive protein GAPDH to bind to Rheb. This leads to greater mTOR-Rheb binding,
resulting in increased mTOR activity in S47 cells and tissues. These data indicate that, along with pH
(Walton et al., 2018), cellular redox status can also regulate mTOR activity, in a manner controlled
by p53. We show that oxidative metabolism in S47 cells is less sensitive to mTOR inhibitors, thus
tying these two phenotypes together; this is not surprising, as a link between mTOR and a number
of cellular metabolic processes is well known (Morita et al., 2013; Schieke et al., 2006).
We see evidence for increased mTOR activity only in certain tissues of the S47 mouse, so the met-
abolic impact of this genetic variant appears to be influenced by tissue type and cellular environ-
ment. At present, we do not know if this tissue specificity is due to differences in GSH level, or to
altered mTOR-Rheb or GAPDH-Rheb interactions in different tissues, or to other parameters. We
also see evidence for some unexpected findings regarding the increase in mTOR activity in S47 cells:
given that mTOR negatively regulates autophagy (Jung et al., 2010), we expected to see differen-
ces in steady state autophagy or autophagic flux in WT and S47 cells, but we found no evidence for
this. This finding may be due to the rather complex relationship between mTOR and autophagy
(Jung et al., 2010; White et al., 2011), and/or that other signaling pathways regulate autophagy
aside from mTOR, including the PI3K pathway, GTPases, and calcium (Yang et al., 2005).
The increased lean content in S47 mice likely contributes to the increased fitness observed in
these mice. Human studies have shown that mTOR activation is crucial for human muscle protein
synthesis (Dickinson and Rasmussen, 2011). Treatment with the well-studied mTOR inhibitor rapa-
mycin blocks the effects of amino acid ingestion on mTOR activity and leads to decreased protein
synthesis in human skeletal muscle (Dickinson and Rasmussen, 2011; Drummond et al., 2009).
Additionally, mTOR signaling driven through IGF-1 plays a key role in promoting muscle hypertrophy
Figure 5 continued
panel). (E–F) Proximity ligation analysis (PLA) was performed in WT and S47 MEFs treated with 50 mM of DEM for 5 hr and analyzed as described in
Figure 4A–B. Scale bar is 30 mm.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. Glutathione depletion by BSO alters GAPDH cross-linking and the GAPDH-Rheb interaction.
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Figure 6. Increased size and improved metabolic efficiency in S47 mice. (A) Nuclear magnetic resonance (NMR) studies revealed S47 mice have
increased body weight, increased fat content and increased lean content, n = 7 WT mice, n = 8 S47 mice. (***) p-value<0.001, (****) p-value<0.0001.
Bar graphs are presented as mean ± SD. (B) Changes in metabolic parameters for WT mice (blue) and S47 mice (red) were determined by using the
Comprehensive Lab Animal Monitoring System for 48 hr. Parameters assessed includes oxygen consumption, carbon dioxide production, respiratory
exchange rate, energy expenditure, total food intake, and locomotor activity. The data are representative of five 6-week old male mice per genotype
and are normalized to total body weight. (C) WT and S47 mice (n = 6–7) were subjected to a treadmill study of increasing intensity over time. Oxygen
consumption (VO2) is normalized to body mass. (D) Mean basal VO2 in WT and S47 mice. (E) VO2 range in WT and S47 mice determined by subtracting
the mean basal VO2 from the VO2 max, obtained during the most strenuous point of exercise at the tail end of the treadmill study. (F) Lactate
Figure 6 continued on next page
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(Coleman et al., 1995; Musarò et al., 2001; Vandenburgh et al., 1991). One caveat of this study,
however, is that we do not directly demonstrate that the increased mTOR activity in S47 mice is
causing their increased lean content or superior performance on treadmill assays. Transient treat-
ment with mTOR inhibitors elicits highly complex and often contrasting effects on energy expendi-
ture and treadmill performance, likely due to the existence of feedback loops and the effect of
inhibitors on multiple organ systems in the mouse. As just two examples: rapamycin has shown con-
trasting effects on energy expenditure in animals, depending on how long mice are treated
(Fang et al., 2013); similarly, treatment of mice with rapamycin has shown limited impact on tread-
mill endurance, despite causing decreased expression of genes involved in mitochondrial biogenesis
and oxidative phosphorylation in the muscle (Ye et al., 2013). Possibly, the most consistent findings
in the literature reflect the general consensus that mTORC1 is involved in mechanisms that drive
increased muscle mass (Goodman, 2019) and that heightened mTOR activity leads to enhanced
muscle recovery after exercise (Song et al., 2017; Yoon, 2017). It remains to be tested if these are
the pathways affected in S47 mice.
We hypothesize that the more efficient metabolism and enhanced fitness provided by the S47
variant may have once provided carriers with a bio-energetic advantage in Sub-Saharan western
Africa, where this variant is most common. For example, those carrying the S47 SNP may have pos-
sessed superior athletic prowess and/or ability to withstand famine (see model, Figure 7). This meta-
bolic advantage may explain the high frequency of this genetic variant in sub-Saharan Africa, despite
the fact that it predisposes individuals to cancer later in life. Another positive selection for this vari-
ant in Africa may include an improved ability to withstand malaria infection: we recently reported
that the S47 variant alters the immune micro-environment in mice and confers improved response to
the malaria toxin hemozoin (Singh et al., 2020).
Our findings provide further support for the growing premise that some tumor suppressor
genetic variants may provide evolutionary selection benefit (Vicens and Posada, 2018). For exam-
ple, women who carry the BRCA1/2 mutation exhibit increased size and enhanced fertility when
compared to controls (Smith et al., 2012). Similarly, people with Li Fraumeni syndrome who inherit
germline mutations in TP53, as well as mice with tumor-derived germline mutations in Tp53, demon-
strate increased fitness endurance (Wang et al., 2013); however, this is due to increased mitochon-
drial content, which we do not see in S47 cells. A common genetic variant in TP53 at codon 72,
encoding proline at amino acid 72, confers increased longevity while conversely causing increased
cancer risk (Zhao et al., 2018). In contrast, the arginine 72 variant of p53 induces increased expres-
sion of LIF, which improves fecundity (Kang et al., 2009). The take home message from all these
studies is that the diverse roles of tumor suppressor proteins like p53 in metabolism, fertility, and fit-
ness may allow for positive selection for certain variants, even at the expense of increased cancer
risk. In mice, this increased cancer risk occurs quite late in life, well past reproductive selection (12–
18 months). More needs to be done to analyze cancer risk in S47 humans. A more comprehensive
understanding of the function of tumor suppressor genetic variants, including the S47 SNP, will
enable improved understanding of cancer risk, along with superior personalized medicine
approaches, with the ultimate goal of improving clinical outcomes and survival of people who carry
this variant.
Figure 6 continued
dehydrogenase (LDH) levels measured in the serum of WT and S47 mice obtained before and after the treadmill study. (*) p-value<0.05, Student’s
t-test.
The online version of this article includes the following source data and figure supplement(s) for figure 6:
Source data 1. Metabolic efficiency source data 1.
Source data 2. Metabolic efficiency source data 2.
Source data 3. Metabolic efficiency source data 3.
Figure supplement 1. Serum metabolites and protein markers pre- and post- exercise.
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Figure 7. Proposed model. (A) Proposed model of how S47 contributes to increased metabolism. The elevated levels of GSH alter the redox state of
the S47 cell, in turn affecting GAPDH conformation and impairing GAPDH-Rheb binding. This results in increased mTOR-Rheb binding, leading to
increased mTOR activity and resulting an overall increase in metabolism in S47 mice, as seen by increased fat and lean content. (B) Broad impact of S47
variant: although providing an adaptive advantage to individuals residing in sub-Saharan Africa at one point in time, it now predisposes modern
humans with this SNP to cancer.
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All cell lines have been confirmed of identity using STR profiling; most were obtained by the Coriell
Institute. All were confirmed to be free of mycoplasma prior to each experiment. WT and S47 MEFs
were generated and maintained as previously described (Jennis et al., 2016). Human WT LCLs (Cat-
alog ID GM18870) and S47 LCLs (Catalog ID GM18871) were obtained from the Coriell Institute
(Camden, New Jersey) and maintained as previously described (Jennis et al., 2016). MEF cultured
cells were grown in DMEM (Corning Cellgro) supplemented with 10% fetal bovine serum (HyClone,
GE Healthcare Life Sciences) and 1% penicillin/streptomycin (Corning Cellgro). Human LCLs were
grown in RPMI (Corning Cellgro) supplemented with 15% heat inactivated fetal bovine serum
(HyClone, GE Healthcare Life Sciences) and 1% penicillin/streptomycin (Corning Cellgro). Cells were
grown in a 5% CO2 humidified incubator at 37˚C. For serum starvation experiments, cells were
starved in DMEM containing 0.1% FBS for 16 hr. Following starvation, DMEM containing 10% FBS
was re-introduced and cells were harvested at 0 min, 10 min, 30 min, 1 hr, 2 hr, and 8 hr after this
point. For glucose starvation experiments, cells were starved in glucose-free DMEM (Thermo Fisher
Scientific 11966025) for 16 hr. Following starvation, DMEM containing 4.5 g/L glucose was re-intro-
duced and cells were harvested at 0 min, 10 min, 30 min, 1 hr, 2 hr, and 5 hr after this point. For
amino acid starvation experiments, cells were starved for 4 hr in EBSS (Thermo Fisher Scientific
24010043) containing 25 mM glucose, 0.5 mM Glutamine, 1X MEM Vitamin (Thermo Fisher Scientific
11120052), 0.2% FBS, 25 mM HEPES, 1X Penicillin/Streptomycin. Following starvation, the same
media recipe now containing 1X MEM Amino Acids (Thermo Fisher 1130051) was re-introduced and
cells were harvested at 0 min, 10 min, 30 min, 1 hr, 2 hr, and 5 hr after this point. For HBSS experi-
ments, cells were washed once with PBS (Corning 21–031-CV) and then incubated with HBSS
(Thermo Fisher Scientific 14025092) for 0, 2, or 6 hr. Viability was assessed using Trypan Blue
(Thermo Fisher Scientific 15250061).
Western blot
For western blot analyses, 50–100 mg of protein was resolved over SDS-PAGE gels using 10%
NuPAGE Bis-Tris precast gels (Life Technologies) and were then transferred onto polyvinylidene
difluoride membranes (IPVH00010, pore size: 0.45 mm; Millipore Sigma). Membranes were blocked
for 1 hr in 5% bovine albumin serum (Sigma Aldrich, A9647). The following antibodies were used for
western blot analyses: phospho-mTOR 1:1000 (Cell Signaling, 2971), mTOR 1:1000 (7C10, Cell Sig-
naling, 2983), phospho-p70S6K1 1:1000 (Cell Signaling, 9205), p70S6K1 1:1000 (Cell Signaling,
9202), GAPDH 1:10,000 (14C10, Cell Signaling, 2118), TFAM 1:2000 (Abcam, ab131607), MTCO1
1:2000 (Abcam, ab14705), SDHA 1:1000 (Cell Signaling, 5839), Tom20 1:100 (F-10, Santa Cruz,
sc17764), phospho-Akt (D9E, Cell Signaling, 4060), p62 1:1000 (Cell Signaling, 5114), LC3B 1:1000
(D11, Cell Signaling, 3868), HSP90 1:1000 (Cell Signaling, 4877S), Rheb 1:1000 (E1G1R, Cell Signal-
ing, 13879), TSC2 1:1000 (D93F12, Cell Signaling, 4308), Akt 1:1000 (Cell Signaling, 9272), Deptor
1:1000 (Novus Bio, NBP1-49674SS), phospho-AMPKa (Cell Signaling, 2535). Rabbit or mouse sec-
ondary antibodies conjugated to horseradish peroxidase were used at a 1:10,000 dilution (Jackson
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Immunochemicals), followed by a 5-min treatment with ECL (Amersham, RPN2232). Protein levels
were detected using autoradiography and densitometry analysis of protein content was conducted
using ImageJ software (NIH, Rockville, MD).
Immunohistochemistry
Tissues were harvested and fixed in formalin overnight at 4˚C, followed by a wash with 1X PBS and
were then placed in 70% ethanol prior to paraffin embedding. The Wistar Institute Histotechnology
Facility performed the tissue embedding and sectioning. For the immunohistochemistry (IHC) stud-
ies, paraffin embedded tissue sections were de-paraffinized in xylene (Fisher, X5-SK4) and re-
hydrated in ethanol (100%–95%-85–75%) followed by distilled water. Samples underwent antigen
retrieval by steaming slides in 10 mM Citrate Buffer (pH 6). Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide and slides were incubated in blocking buffer (Vector Labora-
tories, S-2012) for 1 hr. The slides were incubated with phospho-p70S6K1 (1:100, ThermoFisher Sci-
entific, PA5-37733) or phospho-mTOR (1:100, Cell Signaling, 2971) primary antibody overnight at 4˚
C. The following day, slides were washed with PBS and incubated with HRP-conjugated secondary
antibody for 30 min. Antibody complexes were detected using DAB chromogen (D5637). Light coun-
terstaining was done with hematoxylin. Slides were imaged using the Nikon 80i upright microscope
and at least four fields were taken per section.
Co-immunoprecipitation
Following overnight seeding of WT and S47 immortalized MEFs, the cells were washed with 1X
DPBS and the cell culture medium was replaced with 1% FBS DMEM medium [pyruvate-free DMEM
(Thermo Fisher Scientific #21013024) supplemented with 1% FBS, 1% penicillin/streptomycin, 0.1
mM L-Methionine, 0.5 mM L-Glutamine, and 0.033 mM L-Cystine]. WT cells were treated with PBS
or 3 mM GSH for 24 hr; while the S47 cells were treated with PBS for 5 hr or 24 hr, 100 mM BSO for
24 hr, or 50 mM DEM for 5 hr. Cells were harvested and centrifuged at 500 x g for 10 min at 4˚C.
The cell pellets were resuspended in CHAPS Lysis Buffer (1X DPBS with 0.3% CHAPS and freshly
added protease inhibitors) at 4˚C. Cell disruption was performed by passing the cells through a 23-
gauge needle attached to a 1 ml syringe. The skeletal muscles were homogenized using the Qiagen
Tissue Lyser II. Total cellular homogenates were rotated/nutated at 4˚C for 30 min, and spun at
11,000 x g for 20 min at 4˚C. Protein extracts (3 mg per reaction) were incubated with the Rheb anti-
body (Santa Cruz, sc-271509) overnight at 4˚C. The Rheb-immunocomplexes were captured using
recombinant protein G agarose (Thermo Fisher Scientific, 15920010) at 4˚C for 2 hr. Resins were
washed three times using the CHAPS Lysis Buffer. Equal volumes of 2x Laemmli Sample Buffer were
added to each reaction, samples were heated for 10 min at 100˚C. The Rheb-associated proteins
were analyzed by western blotting, using GAPDH (Cell Signaling, 2118), Rheb (Cell Signaling,
13879), and mTOR (7C10, Cell Signaling, 2983) antibodies.
Mitochondrial metabolism and mTOR inhibition assays
The oxygen consumption rate (OCR) and glycolytic rate were determined using the Seahorse XF
MitoStress Assay and the Seahorse XF Glycolytic Rate Assay, respectively, according to the manufac-
turer’s protocol. Cells were plated one day prior to the assay, LCLs at 100,000 cells/well and MEFs
at 60,000 cells/well. LCLs were treated with 200 nM rapamycin, 100 nM Torin1 or 1 mM Torin1 for 24
hr prior to running the MitoStress Assay. To assess differences in mTOR inhibition, WT and S47 LCLs
were treated with 200 nM rapamycin or 100 nM Torin1 for 0 min, 10 min, 30 min, 1 hr, 2 hr, or 6 hr
and subsequently cells were harvested for western blot analysis. To determine mitochondrial con-
tent, WT and S47 MEFs were incubated with 500 nM of MitoTracker Green (ThermoFisher Scientific,
M7514) for 1 hr at 37˚C. Cells were then spun down, washed once with PBS, spun down and resus-
pended in PBS. The FACSCelesta (BD Biosciences) was used to detect fluorescence and at least
10,000 events were measured per sample.
Metabolite measurements
Media was collected after 24 hr after plating LCLs or MEFs, and the YSI-71000 Bioanalyzer was used
to determine glucose, glutamine, lactate and glutamate levels as previously described
(Londoño Gentile et al., 2013). For the metabolic flux studies, cells were incubated in uniformly
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labeled 13C-glucose (25 mM) as indicated in the figure legends. For intracellular extracts, after incu-
bation, the culture medium was aspirated and cells were washed once in ice-cold PBS. Metabolites
were extracted by adding a solution of methanol/acetonitrile/water (5:3:2) to the well. Plates were
incubated at 4˚C for 5 min on a rocker and then the extraction solution was collected. The metabo-
lite extract was cleared by centrifuging at 15,000 x g for 10 min at 4˚C. Supernatants were trans-
ferred to LC-MS silanized glass vials with PTFE caps and either run immediately on the LC-MS or
stored at  80˚C. LC-MS analysis was performed on a Q Exactive Hybrid Quadrupole-Orbitrap HF-X
MS (ThermoFisher Scientific) equipped with a HESI II probe and coupled to a Vanquish Horizon
UHPLC system (ThermoFisher Scientific). 0.002 ml of sample is injected and separated by HILIC chro-
matography on a ZIC-pHILIC 2.1 mm. Samples were separated by ammonium carbonate, 0.1%
ammonium hydroxide, pH 9.2, and mobile phase B is acetonitrile. The LC was run at a flow rate of
0.2 ml/min and the gradient used was as follows: 0 min, 85% B; 2 min, 85% B; 17 min, 20% B; 17.1
min, 85% B; and 26 min, 85% B. The column was maintained at 45˚C and the mobile phase was also
pre-heated at 45˚C before flowing into the column. The relevant MS parameters were as listed:
sheath gas, 40; auxiliary gas, 10; sweep gas, 1; auxiliary gas heater temperature, 350˚C; spray volt-
age, 3.5 kV for the positive mode and 3.2 kV for the negative mode. Capillary temperature was set
at 325˚C, and funnel RF level at 40. Samples were analyzed in full MS scan with polarity switching at
scan range 65 to 975 m/z; 120,000 resolution; automated gain control (AGC) target of 1E6; and
maximum injection time (max IT) of 100 milliseconds. Identification and quantitation of metabolites
was performed using an annotated compound library and TraceFinder 4.1 software. The ‘M+X’
nomenclature refers to the isotopologue for that given metabolite. Isotopologues are chemically
identical metabolites that differ only in their number of carbon-13 atoms. For instance, ‘M+two cit-
rate’ means that two of the six carbons in citrate are carbon-13 while the other four are carbon-12.
‘M+four citrate’ means that four of the six carbons in citrate are carbon-13 while the other two are
carbon-12. Isotopologue fractional labeling was corrected for carbon-13 natural abundance.
GSH/GSSG abundance and BMH crosslinking
Relative GSH/GSSG abundance was measured using the GSH/GSSG-Glo Assay (Promega catalog
#V6611), according to the manufacturer’s instruction. Immortalized WT and S47 MEFs were gener-
ated and maintained as previously described (Jennis et al., 2016; Leu et al., 2019). For BMH cross-
linking studies, the WT and S47 cells were cultured in 1% FBS DMEM medium and treated with PBS
or 50 mM diethyl maleate (DEM, ThermoFisher Scientific AC114440010) for 5 hr; PBS or 100 mM BSO
(Cayman Chemical item #14484) for 24 hr; or DMSO or 2 mM Erastin (Cayman Chemical item
#17754) for 24 hr. Proteins were extracted from cultured cells or mouse tissue (skeletal muscle,
lungs) using 1X DPBS (Thermo Fisher Scientific 14190144) supplemented with 0.5% IGEPAL CA-630,
1 mM PMSF, 6 mg/ml aprotinin, and 6 mg/ml leupeptin at 4 ˚C. The tissues were homogenized using
the Wheaton Overhead Stirrer. Total cellular homogenates were pulse sonicated using the Branson
digital sonifier set at 39% amplitude. Total protein extracts (100 mg per reaction) were incubated
with or without 1 mM BMH (Thermo Fisher Scientific 22330) for 30 min at 30˚C. The samples were
quenched with an equal volume of 2x Laemmli Sample Buffer (BioRad 1610737) supplemented with
5% b-Mercaptoethanol (BioRad 1610710) and heated for 10 min at 100˚C. The protein samples were
size fractionated on Novex 4–20% Tris-Glycine Mini Gels (Thermo Fisher Scientific XP04200BOX) at
room temperature and subsequently transferred overnight onto Immuno-Blot PVDF membranes
(BioRad 1620177) at 4˚C. The membranes were blocked with 3% nonfat dry milk (BioRad 1706404) in
1X PBST for 30 min at room temperature and incubated with the GAPDH antibody (Cell Signaling
Technology 2118) overnight with rotation/nutation at 4˚C. After washing the blots in 1X PBST, the
membranes were incubated with Donkey anti-Rabbit (Jackson ImmunoResearch 711-036-152) for 2
hr at room temperature. Membrane-immobilized protein detection used ECL western blotting
detection reagents (GE Healthcare RPN2106; Millipore Sigma GERPN2106).
Proximity ligation assay
Cells were grown on Lab-Tek II eight-well chamber slides, and were either untreated, treated with
50 mM diethyl maleate (DEM, ThermoFisher Scientific AC114440010) for 5 hr or treated with 10 mM
of buthionine sulfoximine for 24 hr (BSO, Cayman Chemicals, 83730-53-4) and fixed with 4% parafor-
maldehyde (Electron Microscopy Sciences, 15710). Protein-protein interactions were assessed using
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the PLA Duolink in situ starter kit (Sigma Aldrich, DUO92101) following the manufacturer’s protocol.
The following primary antibodies were used: Rheb 1:50 (B-12, Santa Cruz, sc271509), mTOR 1:500
(7C10, Cell Signaling, 2983), GAPDH 1:1000 (14C10, Cell Signaling, 2118). ImageJ software (NIH,
Rockville, MD) was used to quantify PLA signals.
Immunofluorescence staining
Cells were fixed in 4% paraformaldehyde for 10 min, followed by 3 PBS washes and then permeabili-
zation with 0.25% Triton X-100 for 10 min. Cells were washed 3x with PBS, blocked for 1 hr in a PBS
solution containing 1% bovine serum albumin and 5% normal goat serum (Jackson Immunoresearch
005-000-121). Cells were incubated overnight at 4˚C with the following primary antibodies diluted in
blocking buffer: Rheb 1:800 (Cell Signaling Technologies, #13879), TSC2 1:100 (Cell Signaling Tech-
nologies, #4308), LAMP1 1:50 (Santa Cruz, sc-20011). Cells were washed with PBS and incubated
with the following secondary antibodies at 37˚C for 45 min: Alexa Fluor 594 AffiniPure Goat Anti-
Rabbit IgG (Jackson Immunoresearch 111-585-144) and Alexa Fluor 488 AffiniPure Goat Anti-Mouse
IgG (Jackson Immunoresearch 115-545-062). The cells were mounted with media containing DAPI
and images were captured using the Leica TSC SP5 microscope.
Body composition and metabolic cage studies
WT and S47 mice in a pure C57Bl/6 background are previously described (Jennis et al., 2016). All
mouse studies were performed in accordance with the guidelines in the Guide for the Care and Use
of Laboratory Animals of the NIH and all protocols were approved by the Wistar Institute Institu-
tional Animal Care and Use Committee (IACUC). Mice were fed an ad libitum diet and were housed
in plastic cages with a 12 hr/12 hr light cycle at 22˚C unless otherwise stated. Fat and lean content
were measured in live male mice at 6 weeks of age using nuclear magnetic resonance (NMR) with
the Minispec LF90 (Bruker Biospin, Billerica, MA). Indirect calorimetry was conducted to assess meta-
bolic capabilities in mice (Oxyman/Comprehensive Laboratory Animal Monitoring System (CLAMS);
Columbus Instruments). Data for the WT mice was previously published in supplemental data of
Kung et al., 2016. Six-week-old mice were single caged, provided with water and food ad libitum
and allowed to acclimate to the cages for 2 days. Oxygen consumption (VO2) and carbon dioxide
production (VCO2) were recorded for 48 hr using an air flow of 600 ml/min and temperature of 22˚C.
Respiratory exchange ratio (RER) is calculated as VCO2/VO2 and heat (kcal/h) is calculated by 3.815
+ 1.232*(RER). Photodetectors were used to measure physical activity (Optovarimex System; Colum-
bus Instruments).
Treadmill and serum metabolite studies
Mice were allowed to acclimate to the metabolic treadmill (Columbus Instruments) for 5 min before
beginning their runs. The treadmill was then set to 5 m/min and speed increased by 5 m/min every 2
min until 20 m/min was reached. Upon reaching 20 m/min, the incline was increased by 5˚ every 2
min until reaching a maximum of 25 degrees. Mice were allowed to run at this maximum speed and
incline until exhaustion, defined by the mice spending 10 continuous seconds on the shock grid. Lac-
tate (Nova Biomedical) and glucose (One Touch) measurements were taken using test strips just
prior to treadmill entry and immediately after exhaustion using handheld meters. Tail blood was also
taken prior to treadmill entry and immediately after exhaustion and metabolites measured using the
Vettest serum analyzer (Idexx Laboratories).
Statistical analysis
Unless otherwise stated, all experiments were performed in triplicate. The two-tailed unpaired Stu-
dent t-test was performed. All in vitro data are reported as the mean ± SD unless stated otherwise,
and in vivo are reported as the mean ± SE. Statistical analyses were performed using GraphPad
Prism, p-values are as follows: (*) p-value<0.05, (**) p-value<0.01, (***) p-value<0.001, (****)
p-value<0.0001. For the CLAMs and mouse exercise data, the Wilcoxon rank-sum test was used to
compare the differences between S47 and WT mice.
Gnanapradeepan et al. eLife 2020;9:e55994. DOI: https://doi.org/10.7554/eLife.55994 21 of 25
Research article Cancer Biology
Acknowledgements
This work was supported by R01 CA102184 (MEM), R01 CA139319 (DLG and MEM), R01 CA238611
(MEM), P01 CA114046 (DLG and MEM), T32 CA009071, F32 CA220972 and K99 CA241367 (TB),
R01 CA174761 (KEW), R01 AG043483 and DK098656 (JAB) and the Rodent Metabolic Phenotyping
Core (P30-DK19525), and DP2-CA249951 (ZTS). RSA is partly supported by a Bloomberg Distin-
guished Professorship. The authors acknowledge the Histotechnology, Laboratory Animal and Imag-
ing facilities at the Wistar Institute. The authors are grateful to Allie Lipshutz and Lindsey Schweitzer
for expert technical help, and Matthew Jennis for the mouse weight data.
Additional information
Competing interests
Maureen E Murphy: Senior Editor, eLife. The other authors declare that no competing interests
exist.
Funding
Funder Grant reference number Author
National Cancer Institute R01 CA102184 Maureen E Murphy
National Cancer Institute R01 CA139319 Donna L George
Maureen E Murphy
National Cancer Institute CA238611 Maureen E Murphy
National Cancer Institute P01 CA114046 Donna L George
Maureen E Murphy
National Cancer Institute T32 CA009171 Thibaut Barnoud
National Cancer Institute F32 CA220972 Thibaut Barnoud
National Cancer Institute K99 CA241367 Thibaut Barnoud
National Cancer Institute R01 CA174761 Kathryn E Wellen
National Institute on Aging R01 AG043483 Joseph A Baur
National Institute of Diabetes
and Digestive and Kidney Dis-
eases
R01 DK098656 Joseph A Baur
National Institute of Diabetes
and Digestive and Kidney Dis-
eases
P30 DK19525 Joseph A Baur
National Cancer Institute DP2-CA249951 Zachary T Schug
Bloomberg Family Foundation Rexford Ahima




The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Keerthana Gnanapradeepan, Conceptualization, Formal analysis, Validation, Investigation, Visualiza-
tion, Methodology, Writing - original draft, Writing - review and editing; Julia I-Ju Leu, Conceptuali-
zation, Formal analysis, Investigation, Methodology, Writing - review and editing; Subhasree Basu,
Conceptualization, Formal analysis, Investigation, Writing - review and editing; Thibaut Barnoud,
Conceptualization, Formal analysis, Funding acquisition, Investigation, Writing - review and editing;
Madeline Good, Formal analysis, Investigation; Joyce V Lee, William J Quinn, Che-Pei Kung, Data
curation, Formal analysis, Investigation, Writing - review and editing; Rexford Ahima, Joseph A Baur,
Kathryn E Wellen, Data curation, Funding acquisition, Methodology, Writing - review and editing;
Gnanapradeepan et al. eLife 2020;9:e55994. DOI: https://doi.org/10.7554/eLife.55994 22 of 25
Research article Cancer Biology
Qin Liu, Formal analysis, Methodology, Writing - review and editing; Zachary T Schug, Data curation,
Formal analysis, Funding acquisition, Investigation, Methodology, Writing - review and editing;
Donna L George, Funding acquisition, Methodology, Writing - review and editing; Maureen E Mur-





Joseph A Baur http://orcid.org/0000-0001-8262-6549
Kathryn E Wellen https://orcid.org/0000-0002-2281-0042
Maureen E Murphy https://orcid.org/0000-0001-7644-7296
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of
the animals were handled according to approved institutional animal care and use committee
(IACUC) protocols of the University of Pennsylvania (protocol 804474) and The Wistar Institute (pro-
tocol 201283).





. Transparent reporting form
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.
Source data files are provided for Figure 6 and Figure 2—figure supplement 1.
References
Baar EL, Carbajal KA, Ong IM, Lamming DW. 2016. Sex- and tissue-specific changes in mTOR signaling with age
in C57BL/6J mice. Aging Cell 15:155–166. DOI: https://doi.org/10.1111/acel.12425, PMID: 26695882
Basu S, Gnanapradeepan K, Barnoud T, Kung CP, Tavecchio M, Scott J, Watters A, Chen Q, Kossenkov AV,
Murphy ME. 2018. Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1a. Genes &
Development 32:230–243. DOI: https://doi.org/10.1101/gad.309062.117, PMID: 29463573
Ben-Sahra I, Manning BD. 2017. mTORC1 signaling and the metabolic control of cell growth. Current Opinion in
Cell Biology 45:72–82. DOI: https://doi.org/10.1016/j.ceb.2017.02.012, PMID: 28411448
Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. 2013. Metabolic regulation by p53 family members.
Cell Metabolism 18:617–633. DOI: https://doi.org/10.1016/j.cmet.2013.06.019, PMID: 23954639
Brandes N, Schmitt S, Jakob U. 2009. Thiol-based redox switches in eukaryotic proteins. Antioxidants & Redox
Signaling 11:997–1014. DOI: https://doi.org/10.1089/ars.2008.2285, PMID: 18999917
Budanov AV, Karin M. 2008. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR
signaling. Cell 134:451–460. DOI: https://doi.org/10.1016/j.cell.2008.06.028, PMID: 18692468
Chernorizov KA, Elkina JL, Semenyuk PI, Svedas VK, Muronetz VI. 2010. Novel inhibitors of glyceraldehyde-3-
phosphate dehydrogenase: covalent modification of NAD-binding site by aromatic thiols. Biochemistry.
Biokhimiia 75:1444–1449. DOI: https://doi.org/10.1134/s0006297910120047, PMID: 21314614
Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz RJ. 1995. Myogenic vector
expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in
transgenic mice. Journal of Biological Chemistry 270:12109–12116. DOI: https://doi.org/10.1074/jbc.270.20.
12109, PMID: 7744859
Gnanapradeepan et al. eLife 2020;9:e55994. DOI: https://doi.org/10.7554/eLife.55994 23 of 25
Research article Cancer Biology
Dickinson JM, Rasmussen BB. 2011. Essential amino acid sensing, signaling, and transport in the regulation of
human muscle protein metabolism. Current Opinion in Clinical Nutrition and Metabolic Care 14:83–88.
DOI: https://doi.org/10.1097/MCO.0b013e3283406f3e, PMID: 21076294
Drummond MJ, Fry CS, Glynn EL, Dreyer HC, Dhanani S, Timmerman KL, Volpi E, Rasmussen BB. 2009.
Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein
synthesis. The Journal of Physiology 587:1535–1546. DOI: https://doi.org/10.1113/jphysiol.2008.163816,
PMID: 19188252
Fang Y, Westbrook R, Hill C, Boparai RK, Arum O, Spong A, Wang F, Javors MA, Chen J, Sun LY, Bartke A.
2013. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metabolism 17:456–
462. DOI: https://doi.org/10.1016/j.cmet.2013.02.008, PMID: 23473038
Feng Z, Zhang H, Levine AJ, Jin S. 2005. The coordinate regulation of the p53 and mTOR pathways in cells.
PNAS 102:8204–8209. DOI: https://doi.org/10.1073/pnas.0502857102, PMID: 15928081
Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ. 2007. The regulation of AMPK beta1, TSC2,
and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in
modulating the IGF-1-AKT-mTOR pathways. Cancer Research 67:3043–3053. DOI: https://doi.org/10.1158/
0008-5472.CAN-06-4149, PMID: 17409411
Gnanapradeepan K, Basu S, Barnoud T, Budina-Kolomets A, Kung CP, Murphy ME. 2018. The p53 tumor
suppressor in the control of metabolism and ferroptosis. Frontiers in Endocrinology 9:124. DOI: https://doi.org/
10.3389/fendo.2018.00124, PMID: 29695998
Goodman CA. 2019. Role of mTORC1 in mechanically induced increases in translation and skeletal muscle mass.
Journal of Applied Physiology 127:581–590. DOI: https://doi.org/10.1152/japplphysiol.01011.2018,
PMID: 30676865
Green NS, Reisler E, Houk KN. 2001. Quantitative evaluation of the lengths of homobifunctional protein cross-
linking reagents used as molecular rulers. Protein Science 10:1293–1304. DOI: https://doi.org/10.1110/ps.
51201
Hasty P, Sharp ZD, Curiel TJ, Campisi J. 2013. mTORC1 and p53: clash of the gods? Cell Cycle 12:20–25.
DOI: https://doi.org/10.4161/cc.22912, PMID: 23255104
Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49–53.
DOI: https://doi.org/10.1126/science.1905840, PMID: 1905840
Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK,
Wang X, Bell DA, Li X, Garlick DS, Liu Q, Hollstein M, George DL, Murphy ME. 2016. An African-specific
polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes &
Development 30:918–930. DOI: https://doi.org/10.1101/gad.275891.115, PMID: 27034505
Jung CH, Ro SH, Cao J, Otto NM, Kim DH. 2010. mTOR regulation of autophagy. FEBS Letters 584:1287–1295.
DOI: https://doi.org/10.1016/j.febslet.2010.01.017, PMID: 20083114
Kang HJ, Feng Z, Sun Y, Atwal G, Murphy ME, Rebbeck TR, Rosenwaks Z, Levine AJ, Hu W. 2009. Single-
nucleotide polymorphisms in the p53 pathway regulate fertility in humans. PNAS 106:9761–9766. DOI: https://
doi.org/10.1073/pnas.0904280106, PMID: 19470478
Kung CP, Leu JI, Basu S, Khaku S, Anokye-Danso F, Liu Q, George DL, Ahima RS, Murphy ME. 2016. The P72R
polymorphism of p53 predisposes to obesity and metabolic dysfunction. Cell Reports 14:2413–2425.
DOI: https://doi.org/10.1016/j.celrep.2016.02.037, PMID: 26947067
Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274–293. DOI: https://
doi.org/10.1016/j.cell.2012.03.017, PMID: 22500797
Lee MN, Ha SH, Kim J, Koh A, Lee CS, Kim JH, Jeon H, Kim DH, Suh PG, Ryu SH. 2009. Glycolytic flux signals to
mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of rheb. Molecular and
Cellular Biology 29:3991–4001. DOI: https://doi.org/10.1128/MCB.00165-09, PMID: 19451232
Leu JI, Murphy ME, George DL. 2019. Mechanistic basis for impaired ferroptosis in cells expressing the African-
centric S47 variant of p53. PNAS 116:8390–8396. DOI: https://doi.org/10.1073/pnas.1821277116, PMID: 30
962386
Liu GY, Sabatini DM. 2020. mTOR at the nexus of nutrition, growth, ageing and disease. Nature Reviews
Molecular Cell Biology 21:183–203. DOI: https://doi.org/10.1038/s41580-019-0199-y, PMID: 31937935
Londoño Gentile T, Lu C, Lodato PM, Tse S, Olejniczak SH, Witze ES, Thompson CB, Wellen KE. 2013. DNMT1
is regulated by ATP-citrate lyase and maintains methylation patterns during adipocyte differentiation.
Molecular and Cellular Biology 33:3864–3878. DOI: https://doi.org/10.1128/MCB.01495-12, PMID: 23897429
Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. 2005. Rheb binds and regulates the mTOR kinase. Current
Biology 15:702–713. DOI: https://doi.org/10.1016/j.cub.2005.02.053, PMID: 15854902
Morita M, Gravel SP, Chénard V, Sikström K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C,
McLaughlan S, Nouet Y, Pause A, Pollak M, Gottlieb E, Larsson O, St-Pierre J, Topisirovic I, Sonenberg N.
2013. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational
regulation. Cell Metabolism 18:698–711. DOI: https://doi.org/10.1016/j.cmet.2013.10.001, PMID: 24206664
Murphy ME, Liu S, Yao S, Huo D, Liu Q, Dolfi SC, Hirshfield KM, Hong CC, Hu Q, Olshan AF, Ogundiran TO,
Adebamowo C, Domchek SM, Nathanson KL, Nemesure B, Ambs S, Blot WJ, Feng Y, John EM, Bernstein L,
et al. 2017. A functionally significant SNP in TP53 and breast Cancer risk in African-American women. Npj
Breast Cancer 3:5. DOI: https://doi.org/10.1038/s41523-017-0007-9, PMID: 28649645
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